PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Introduces New PKD1 & PKD2 Antibodies - Protein kinase D (PKD), a serine/threonine kinase originally described as a novel PKC family member and termed PKCm (1), belongs to the calcium calmodulin superfamily of kinases (2-3)
AnaSpec Introduces New PKD1 & PKD2 Antibodies

 

NewswireToday - /newswire/ - San Jose, CA, United States, 2008/10/21 - Protein kinase D (PKD), a serine/threonine kinase originally described as a novel PKC family member and termed PKCm (1), belongs to the calcium calmodulin superfamily of kinases (2-3).

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Three mammalian isoforms have so far been described - PKD1/PKCm, PKD2 and PKD3/PKCn; these isoforms show a high degree of homology, especially in their catalytic domain (4-5). PKDs are major targets for tumor promoting phorbol esters; they are activated via G protein-coupled receptors (GPCRs) and their activation is also dependent on PKC activation (5). PKDs have been implicated in numerous cellular functions, including signal transduction as well as cell survival, migration, differentiation, and proliferation (4-6). They are important regulators of secretory transport at the trans-golgi network (7). Of the three isoforms, PKD1 is the best characterized. It is involved in the regulation of Golgi function, cell proliferation and apoptosis (8) and it mediates oxidative stress signaling regulating cellular detoxification and survival (9). PKD2 has been found to phosphorylate histone H1 more efficiently than aldolase in vitro (10).

AnaSpec is pleased to announce the release of isoform specific PKD1 and PKD2 antibodies. These antibodies were raised using sequences from the C-terminus of PKD1 and PKD2. Anti-PKD1 only recognizes PKD1 and not PKD2 and PKD3. Anti-PKD2 only recognizes PKD2 and not PKD1 or PKD3.

About AnaSpec, Inc.

AnaSpec (anaspec.com) is a leading provider of integrated proteomics solutions to the world’s largest biotech, pharmaceutical, and academic research institutions. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and combinatorial chemistry.

REFERENCES
1. Johannes, FJ. et al. J. Biol. Chem. 269, 6140 (1994).
2. Manning, G. et al. Science 298, 1912 (2002).
3. Van Lint, J. et al. Trends Cell Biol. 12, 193 (2002).
4. Waldron, RT. et al. J. Biol. Chem. 276, 32606 (2001).
5. Auer, A. et al. Mol. Bio. Cell. 16, 4375 (2005).
6. Rozengurt, E. et al. J. Biol. Chem. 208, 13205 (2005).
7. Yeaman, C. et al. Nature Cell Biol. 6, 106 (2004).
8. Rykx, A. et al. FEBS Lett. 546, 81 (2003).
9. Döppler, H. & P. Storz, et al. J. Biol. Chem. 282, 31873 (2007).
10. Sturany, S. et al. J. Biol. Chem. 276, 3310 (2001).

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Introduces New PKD1 & PKD2 Antibodies

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Ping Yang 
408-452-5055 ping[.]anaspec.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Ipsen Announces Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival
First Patient Treated with Microscopic Beads Pre-loaded with A Targeted Cancer Drug and Visible on CT Scans
BTG Plc Acquires Roxwood Medical
BTG and Mirada Medical Sign Three-Year Software Development Agreement
U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)